Biventricular Impella use in pediatric patients with severe graft dysfunction from acute rejection after heart

Ashish A Ankola1, Jennie McAllister1, Mariel E Turner1

  • 1Division of Pediatric Cardiology, Morgan Stanley Children's Hospital of New York Presbyterian, Columbia University Irving Medical Center, New York, New York.

Artificial Organs
|August 21, 2019
PubMed

Insights

Biventricular Impella devices offer a less invasive alternative for pediatric heart transplant patients experiencing severe graft dysfunction. This case series demonstrates successful outcomes with bilateral Impella support, improving hemodynamics and aiding survival to discharge.

Area of Science:

  • Pediatric Cardiology
  • Transplantation Medicine
  • Mechanical Circulatory Support

Background:

  • Severe graft dysfunction post-pediatric heart transplant leads to significant morbidity and mortality.
  • Traditional treatments include inotropes and extracorporeal membrane oxygenation (ECMO).
  • Percutaneous ventricular assist devices are emerging as less invasive alternatives.

Observation:

  • A case series of three pediatric heart transplant recipients with severe biventricular dysfunction due to presumed rejection.
  • Patients required maximal inotropic support without improvement.
  • Simultaneous percutaneous placement of Impella CP and RP devices (Biventricular Impella) was performed.

Findings:

  • Pre-implantation left ventricular ejection fractions (LVEF) were critically low (23-40%).
  • Implantation resulted in successful hemodynamic stabilization.
  • All patients were weaned off support, survived to discharge, and showed improved cardiac function post-removal.

Implications:

  • Biventricular Impella configuration (BiPella) is a viable temporary mechanical circulatory support option for pediatric patients with severe graft dysfunction.
  • This approach may reduce reliance on ECMO.
  • Further research into BiPella for pediatric heart transplant recipients is warranted.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
261
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
196
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
250
Quantifying and Rejecting Outliers: The Grubbs Test01:02

Quantifying and Rejecting Outliers: The Grubbs Test

Sometimes, a data set can have a recorded numerical observation that greatly  deviates from the rest of the data. Assuming that the data is normally distributed, a statistical method called the Grubbs test can be used to determine whether the observation is truly an outlier.  To perform a two-tailed Grubbs test, first, calculate the absolute difference between the outlier and the mean. Then, calculate the ratio between this difference and the standard deviation of the sample. This...
3.6K
Hypothesis: Accept or Fail to Reject?01:17

Hypothesis: Accept or Fail to Reject?

The outcome of any hypothesis testing leads to rejecting or not rejecting the null hypothesis. This decision is taken based on the analysis of the data, an appropriate test statistic, an appropriate confidence level, the critical values, and P-values. However, when the evidence suggests that the null hypothesis cannot be rejected, is it right to say, 'Accept' the null hypothesis?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
29.3K